Press releases
-
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Ophthalmology
- Inherited Retinal Diseases
-
ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
- sepofarsen
- Leber congenital amaurosis
- AAPOS
- Inherited Retinal Diseases
-
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
- Inherited Retinal Diseases
-
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
- Inherited Retinal Diseases
-
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
- QR-421a
- Usher syndrome
- NsRP
- Clinical trial
- Inherited Retinal Diseases
-
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
- QR-421a
- Usher syndrome
- Retinitis pigmentosa
- NsRP
- RNA therapies
- rare disease
- Inherited Retinal Diseases
-
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
- Event
- Investor Conference
- biotechnology
-
ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
- biotechnology
- Inherited Retinal Diseases
- RNA therapies
- Daniel A. de Boer
- Financial Results
-
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
- QR-421a
- Usher syndrome
- Usher syndrome
- QR-421a
- Paul Yang
- MD
- PhD
- Event
- Inherited Retinal Diseases
-
ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
- sepofarsen
- LCA10
- Clinical trial
- Inherited Retinal Diseases
- Leber congenital amaurosis
-
ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
- Event
- Investor Conference
-
ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
- Investor Conference
- Event
-
ProQR Announces Third Quarter 2020 Operating and Financial Results
- Ophthalmology
- biotechnology
- RNA therapies
- sepofarsen
- QR-421a
- QR-1123
- Leber congenital amaurosis
- Retinitis pigmentosa
- Financial Results
-
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)
- Sepofarsen (QR-110)
- Leber congenital amaurosis
- sepofarsen
- AAO
- LCA10
- Ophthalmology
- biotechnology
- Leber congenital amaurosis
-
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
- Chief Scientific Officer
- Management
- biotechnology
- leadership
- Ophthalmology
- Naveed Shams
- MD
- PhD
-
ProQR Announces Virtual Presentations at Scientific Conferences
- Euretina
- AAOpt
- sepofarsen
- Leber congenital amaurosis
- LCA10
- biotechnology
- drug development
- Ophthalmology
-
ProQR to Participate in Upcoming Investor Conferences
- biotechnology
- RNA therapies
- Ophthalmology
- Inherited Retinal Diseases
-
ProQR Announces Second Quarter 2020 Operating and Financial Results
- Ophthalmology
- biotechnology
- RNA therapies
- sepofarsen
- QR-421a
- QR-1123
- Leber congenital amaurosis
- Retinitis pigmentosa
-
ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy
- Scientific Advisory Board
- leadership
- RNA therapies
- biotechnology
-
ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
- biotechnology
- RNA therapies
-
ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen
- Sepofarsen (QR-110)
- Leber congenital amaurosis
- sepofarsen
- RNA therapies
- biotechnology
- Ian M. MacDonald
-
ProQR Announces Expert Perspectives Conference Call Series
- biotechnology
- Usher syndrome
- QR-421a
-
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)
- Sepofarsen (QR-110)
- Leber congenital amaurosis
- biotechnology
- drug development
- Ophthalmology
- RNA therapies
- sepofarsen
- Leber congenital amaurosis
- Stephen Russell
-
ProQR Announces Annual Meeting of Shareholders
- biotechnology
- drug development
- Annual General Meeting